Many clinical trials of new cancer drugs may be inappropriately excluding some people with “Duffy-null phenotype,” a trait found predominantly in people of African or Middle Eastern descent, researchers at Dana-Farber Cancer Institute and Queen Mary University of London report in a new study.
Pharmalittle: We’re reading about Amazon delivering Zepbound, hemophilia treatments, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more
March 13, 2024